



HOUSE COMMITTEE ON APPROPRIATIONS

FISCAL NOTE

HOUSE BILL NO. 1280

PRINTERS NO. 1698

PRIME SPONSOR: Baker

COST / (SAVINGS)

FUND	FY 2016/17	FY 2017/18
General Fund	See Fiscal Impact	See Fiscal Impact

SUMMARY: House Bill 1280, Printer's Number 1698, establishes the Fair Access to Cancer Treatment Act. This legislation is effective in 60 days.

ANALYSIS: With this legislation, health insurance plans that cover treatments for stage IV, metastatic cancers will not be able to limit or exclude innovative drugs for patients if the drugs have been approved by the U.S. Food and Drug Administration and are consistent with best practices for stage IV, metastatic cancer treatment. Specifically, patients will not have to first prove that they failed to respond to a different drug or drugs before they are provided coverage.

HB 1280 will apply to insurance plans issued, delivered or renewed on or after the bill's effective date.

FISCAL IMPACT: According to the American Cancer Society, 77,710 Pennsylvanians (0.6% of the state's population) are projected to be diagnosed with cancer in 2017. An unknown percentage of cancer diagnoses will progress to stage IV and these individuals could potentially choose innovative drugs without progressing through different drug treatment regimens. The difference in the cost of these treatment regimens cannot be calculated, therefore enactment of this legislation would have an unknown impact on Commonwealth funds.

PREPARED BY: Ann Bertolino
House Appropriations Committee (R)

DATE: May 24, 2017

Estimates are calculated using the best information available. Actual costs and revenue impact incurred may vary from estimates.